+136.0%
CMS vs GSK
+102.0%
+34.0%
-29.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.2% | -1.2% | +1.0% | +0.2% |
| 7D | -1.1% | -1.1% | 0.0% | -0.8% |
| 30D | +6.6% | +7.8% | -1.3% | +4.0% |
| 3M | +0.8% | +0.3% | +0.5% | +0.4% |
| 6M | -3.3% | +3.4% | -6.8% | -4.8% |
| YTD | +2.7% | +5.9% | -3.2% | -0.1% |
| 1Y | -4.0% | +8.2% | -12.2% | -7.4% |
| 3Y | +37.6% | +65.3% | -27.7% | +11.2% |
| 5Y | +35.4% | +43.3% | -7.9% | +13.7% |
| 10Y | +136.0% | +102.9% | +33.1% | +70.4% |
| All | +136.0% | +102.0% | +34.0% | +70.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling